MIRA INFORM REPORT

 

 

Report Date :

04.12.2013

 

IDENTIFICATION DETAILS

 

Name :

JAWA PHARMACEUTICALS (PVT) LIMITED (JPPL)

 

 

Registered Office :

112/10, Quaid-e-Azam Industrial Area, Kot Lakhpat, Lahore

 

 

Country :

Pakistan

 

 

Date of Incorporation :

22.02.1987

 

 

Com. Reg. No.:

0015689

 

 

Legal Form :

Private Limited company

 

 

Line of Business :

Manufacturing of Pharmaceutical Products (Medicines)

 

 

No. of Employees :

27

 

RATING & COMMENTS

 

MIRA’s Rating :

Ba

 

RATING

STATUS

PROPOSED CREDIT LINE

41-55

Ba

Overall operation is considered normal. Capable to meet normal commitments.

Satisfactory

 

Status :

Satisfactory

Payment Behaviour :

No complaints

Litigation :

Clear

 

 

NOTES :

Any query related to this report can be made on e-mail: infodept@mirainform.com while quoting report number, name and date.

 

ECGC Country Risk Classification List – March 31st, 2013

 

Country Name

Previous Rating

(31.12.2012)

Current Rating

(31.03.2013)

Pakistan

B2

B2

 

Risk Category

ECGC Classification

Insignificant

 

A1

Low

 

A2

Moderate

 

B1

High

 

B2

Very High

 

C1

Restricted

 

C2

Off-credit

 

D

 

 

PAKISTAN - ECONOMIC OVERVIEW

 

Decades of internal political disputes and low levels of foreign investment have led to slow growth and underdevelopment in Pakistan. Agriculture accounts for more than one-fifth of output and two-fifths of employment. Textiles account for most of Pakistan's export earnings, and Pakistan's failure to expand a viable export base for other manufactures has left the country vulnerable to shifts in world demand. Official unemployment is under 6%, but this fails to capture the true picture, because much of the economy is informal and underemployment remains high. Over the past few years, low growth and high inflation, led by a spurt in food prices, have increased the amount of poverty - the UN Human Development Report estimated poverty in 2011 at almost 50% of the population. Inflation has worsened the situation, climbing from 7.7% in 2007 to almost 12% for 2011, before declining to 10% in 2012. As a result of political and economic instability, the Pakistani rupee has depreciated more than 40% since 2007. The government agreed to an International Monetary Fund Standby Arrangement in November 2008 in response to a balance of payments crisis. Although the economy has stabilized since the crisis, it has failed to recover. Foreign investment has not returned, due to investor concerns related to governance, energy, security, and a slow-down in the global economy. Remittances from overseas workers, averaging about $1 billion a month since March 2011, remain a bright spot for Pakistan. However, after a small current account surplus in fiscal year 2011 (July 2010/June 2011), Pakistan's current account turned to deficit in fiscal year 2012, spurred by higher prices for imported oil and lower prices for exported cotton. Pakistan remains stuck in a low-income, low-growth trap, with growth averaging about 3% per year from 2008 to 2012. Pakistan must address long standing issues related to government revenues and energy production in order to spur the amount of economic growth that will be necessary to employ its growing and rapidly urbanizing population, more than half of which is under 22. Other long term challenges include expanding investment in education and healthcare, adapting to the effects of climate change and natural disasters, and reducing dependence on foreign donors

Source : CIA


Company name

 

JAWA PHARMACEUTICALS (PVT) LIMITED (JPPL)

 

 

GENERAL INFORMATION

 

Business Name

JAWA PHARMACEUTICALS (PVT) LIMITED (JPPL)

Address

Head Office / Registered Office:

112/10, Quaid-e-Azam Industrial Area, Kot Lakhpat, Lahore.

Telephone

(+92) (42) 35142041 - 5, 35111147

Fax

(+92) (42) 35110906

Mobile

(+92) (321) 4022271 Mr. Muhammad Baqir Jawa - Director

Email

md@jawagroup.com; info@jawagroup.com; import@jawagroup.com; export@jawagroup.com

Website

http://www.jawagroup.com/jawa-pharma-human/about-us.htm

Business activities

Manufacturing of Pharmaceutical Products (Medicines)

 

 

Registry Details

 

CRO Registration Number

0015689

Date of Registration

February 22, 1987

 

Other registry & certification details:

 

Current Legal Form

Private Limited company

National Tax Registration Number

0786475-2

Date of Registration

July 09, 1996

GST Registration Number

Undetermined

Date of Registration

Undetermined

Chamber of Commerce & Industry

Lahore Chamber of Commerce and Industry

Date of Registration

Undetermined

ISO Certification

ISO 9001:2000

Date of Registration & Expiry

May 05, 2006

Other certifications

None

Date of Registration & Expiry

None

 

Capital

 

Type

No. of Shares

Par Value

Total Value

Authorized

500,000

RS. 100/-

Rs.50,000,000/-

Issued, Subscribed & Paid-Up

269,790

RS. 100/-

Rs.26,979,000/-

 

History

 

Who started

Not Disclosed

When started

1967

Change in management

No Change

Year of change

N/A

Change in legal status

Not Disclosed

Year of change

N/A

Change in business address

Garden town Karachi to Kot Lakhpat Lahore

Year of change

1982

 

 

PRINCIPALS (SPONSORS)

 

Name

Designation

Number of Shares

Nationality

Appointment Date (Last)

Mr. Sajid Ali Jawa

CEO/Director

141,110

Pakistani

30-09-2009

Mrs. Saeeda Fatima

Directors

25,160

Pakistani

30-09-2009

Mr. M. Baqir Jawa

Directors

51,760

Pakistani

30-09-2009

Mr. M. Raza Jawa

Directors

51,760

Pakistani

30-09-2009

 

 

KEY MANAGEMENT

 

Name

 

Position in organization

Qualification

Years in employment

Mr. Sajid Ali Jawa

Chief Executive Officer

 

  Not Provided

 

Mr. Abid Raza

Finance Manager

8 years

Mr. Faisal Suleman

Marketing Manager

 

Mr. Shahzad Hassan

Company Secretary

 

 

Statutory offices

 

Statutory Auditors

M/s. Phinehas & Co. Chartered Accountants

Legal Advisory Services

M/s. Nadeem Nazir Law Associates

 

 

BANKERS

 

Bank name

Approved financing limits

Habib Bank Limited

67,000,000

 


 

DETAILS OF BUSINESS ACTIVITIES

 

The primary focus of the concern is manufacturing of Pharmaceutical Medicines. The company aims to provide quality pharmaceutical products to serve the country and globally. The company started on a small scale and has expanded with the demand of the customers worldwide.

 

 

Purchases (Incl. Imports)

Imports from

India, China

Importing terms

L/C

Local (%)

50

Local buying terms

30-60 Days credit

 

Sales (Incl. Exports)

Exports to

Afghanistan, Myanmar and Sri lanka

Exporting terms

L/C

Local (%)

Not Provided

Local selling terms

Not Provided

 

 

Additional information (Extracts from official website of the organization):

Ambition to get success is a driving force for any noble aim. No ambition can germinate without seed of commitment and light of consistent effort. By grace of God, the immense contribution of Jawa Pharmaceuticals towards the health care of the masses is an unprecedented glittering mark of strenuous effort and consolidated strategies.

 

 Jawa Pharmaceuticals was established with the objective of developing medicines to cure suffering humanity. Its main concern was to earn idea-breeding minds by grasping the finger of progress in the field of science and research.

 

 

NUMBER OF EMPLOYEES

 

Nature of employment

Current Year

Previous Year

All Staff

27

27

Total

27

27

 

 

BUSINESS FACILITIES

 

Head office Address

Owned / Rented

Area (approx)

112/10, Quaid-e-Azam Industrial Area, Kot Lakhpat, Lahore

Owned

Five (5) Kanal

Factory Address

Owned / Rented

Area (approx)

 

Not provided

Warehouse Address

Owned / Rented

Area (approx)

 

Not provided

 

 

MARKET REPUTATION

 

During the market check of JPPL, we contacted various suppliers / customers / competitors of the subject company. In their opinion subject company is a good player of the industry and enjoys good reputation in the market. Market sources further mentioned that JPPL is known as a profitable and prosperous business in the industry. No complaints or disputes were reported during the market check.

 

 

BUSINESS PERFORMANCE

 

The contact person declined to share financial information.

 

 

INTERVIEW & REPORTER COMMENTS

 

Contact person

Mr. Abid

Position

Manager Finance.

Comments

Contact person confirmed the business operations; he provided the business information but decline to share the financial information.

During physical visit we observed different production and trading activities.

Employees were observed busy in their respective tasks.

 

 

 

 


 

FOREIGN EXCHANGE RATES

 

Currency

Unit

Indian Rupees

US Dollar

1

Rs.62.34

UK Pound

1

Rs.102.06

Euro

1

Rs.84.46

 

 

INFORMATION DETAILS

 

Report Prepared by :

NIS

 

 

RATING EXPLANATIONS

 

RATING

STATUS

 

 

PROPOSED CREDIT LINE

>86

Aaa

Possesses an extremely sound financial base with the strongest capability for timely payment of interest and principal sums

 

Unlimited

71-85

Aa

Possesses adequate working capital. No caution needed for credit transaction. It has above average (strong) capability for payment of interest and principal sums

 

Large

56-70

A

Financial & operational base are regarded healthy. General unfavourable factors will not cause fatal effect. Satisfactory capability for payment of interest and principal sums

 

Fairly Large

41-55

Ba

Overall operation is considered normal. Capable to meet normal commitments.

 

Satisfactory

26-40

B

Capability to overcome financial difficulties seems comparatively below average.

 

Small

11-25

Ca

Adverse factors are apparent. Repayment of interest and principal sums in default or expected to be in default upon maturity

 

Limited with full security

<10

C

Absolute credit risk exists. Caution needed to be exercised

 

 

Credit not recommended

--

NB

New Business

 

--

 

This score serves as a reference to assess SC’s credit risk and to set the amount of credit to be extended. It is calculated from a composite of weighted scores obtained from each of the major sections of this report. The assessed factors and their relative weights (as indicated through %) are as follows:

 

Financial condition (40%)            Ownership background (20%)                 Payment record (10%)

Credit history (10%)                    Market trend (10%)                                Operational size (10%)

 

PRIVATE & CONFIDENTIAL : This information is provided to you at your request, you having employed MIPL for such purpose. You will use the information as aid only in determining the propriety of giving credit and generally as an aid to your business and for no other purpose. You will hold the information in strict confidence, and shall not reveal it or make it known to the subject persons, firms or corporations or to any other. MIPL does not warrant the correctness of the information as you hold it free of any liability whatsoever. You will be liable to and indemnify MIPL for any loss, damage or expense, occasioned by your breach or non observance of any one, or more of these conditions

This report is issued at your request without any risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL) or its officials.